Inmune Bio Inc Stock Price, News & Analysis

INmune Bio (NASDAQ: INMB) presented data at the HER2 Targeted Therapy Summit, demonstrating that INB03™ effectively decreases MUC4 expression in trastuzumab-resistant HER2+ breast cancer models. This treatment not only reverses resistance to trastuzumab but also enhances the immunologically active tumor microenvironment (TME). Key findings indicate a significant increase in activated natural killer (NK) cells and anti-tumor macrophages when combining INB03 with trastuzumab. The company aims to advance INB03 into a Phase II trial, aiming for improved outcomes in patients with breast cancer resistant to current treatments.

On May 23, 2022, INmune Bio (NASDAQ: INMB) announced that the FDA placed their Investigational New Drug (IND) application for XPro™ in Alzheimer's treatment on clinical hold, pending additional information regarding Chemistry Manufacturing and Controls (CMC). The official hold letter is expected in approximately 30 days. Meanwhile, the Phase 2 trial for XPro™ continues to enroll patients in Australia. XPro™ is designed to inhibit soluble TNF, potentially reducing neuroinflammation in neurologic diseases.

INmune Bio (NASDAQ: INMB) announced that David Moss, CFO, will present at the H.C. Wainwright Global Hybrid Investment Conference from May 23-26, 2022, at the Fontainebleau Hotel in Miami Beach, FL. The presentation is scheduled for May 24, 2022, at 10:00 AM ET. Moss will also be available for one-on-one meetings, which can be requested through the conference registration link. INmune Bio is focused on immunological therapies targeting the innate immune system, with several candidates in clinical trials for various conditions.

INmune Bio announced that data on XPro™'s ability to promote remyelination in a cuprizone model of multiple sclerosis will be presented on May 10, 2022. Research by Professor Lesley Probert reveals that XPro™ enhances macrophage phagocytosis of myelin debris, aiding in the remyelination process. Previous findings have indicated that XPro™ promotes remyelination in Alzheimer’s patients after a successful Phase I trial. This represents a promising development in neurodegenerative disease treatment.

INmune Bio (NASDAQ: INMB) has dosed its first patient in a Phase II trial for XPro1595, targeting mild Alzheimer’s disease. Financial results for Q1 2022 reveal a net loss of $6.9 million, up from $4.6 million the previous year, with revenues of $0.2 million. R&D expenses rose to $4.3 million, while cash reserves stood at $66.7 million as of March 31, 2022. Upcoming milestones include top-line results from pivotal trials expected in 2023, supporting the potential of their DN-TNF and INKmune platforms against various malignancies.

INmune Bio, Inc. (NASDAQ: INMB) is set to host a conference call and webcast on May 5, 2022, at 4:30 PM ET to discuss first-quarter results ending March 31, 2022, and provide a corporate update. The call can be accessed via dial-in numbers and a live audio webcast link. The company develops therapies targeting the innate immune system, with key products in clinical trials for conditions such as cancer and Alzheimer's disease. Investors are advised that outcomes of ongoing clinical trials remain uncertain as they await FDA approvals.

Boca Raton, FL, April 25, 2022 – INmune Bio (NASDAQ: INMB) announced participation in the B. Riley Neuro & Ophthalmology Conference on April 28, 2022. RJ Tesi, MD, President and CEO, will engage in a fireside chat at 11:00 am ET. This invitation-only event caters to B. Riley Securities' institutional clients. INmune Bio is focused on using the innate immune system to develop treatments for diseases such as cancer and Alzheimer's, with products like INB03™ and XPro™ in clinical trials.

INmune Bio (NASDAQ: INMB) has initiated patient enrollment for a crucial six-month Phase 2 trial assessing XPro1595 in patients with mild Alzheimer's disease (AD). This multicenter, randomized, placebo-controlled study aims to evaluate cognitive function and improvement in biomarkers associated with neuroinflammation. Following positive results from the Phase 1 trial, which showed a reduction in neuroinflammation and improvements in neurorepair biomarkers, the company anticipates enrolling 201 patients across the U.S., Australia, and Canada.

INmune Bio (NASDAQ: INMB) has announced significant findings regarding its product INB03 for treating trastuzumab-resistant MUC4 HER2+ breast cancer. Data from animal models indicate that INB03 effectively decreases MUC4 expression, reversing resistance to trastuzumab and tyrosine kinase inhibitors while enhancing an active tumor microenvironment. This research was presented at the American Association of Cancer Research Annual Meeting. Previous studies reveal MUC4 expression correlates with poorer survival outcomes. INB03 is poised for further clinical testing.